Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Intra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal Evolution and Clinical Implications.

Cresswell GD, Apps JR, Chagtai T, Mifsud B, Bentley CC, Maschietto M, Popov SD, Weeks ME, Olsen ØE, Sebire NJ, Pritchard-Jones K, Luscombe NM, Williams RD, Mifsud W.

EBioMedicine. 2016 Jul;9:120-129. doi: 10.1016/j.ebiom.2016.05.029. Epub 2016 May 27.

2.

Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.

Charles AK, Brown KW, Berry PJ.

Am J Pathol. 1998 Sep;153(3):991-1000.

3.

Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.

Chagtai T, Zill C, Dainese L, Wegert J, Savola S, Popov S, Mifsud W, Vujanić G, Sebire N, Le Bouc Y, Ambros PF, Kager L, O'Sullivan MJ, Blaise A, Bergeron C, Mengelbier LH, Gisselsson D, Kool M, Tytgat GA, van den Heuvel-Eibrink MM, Graf N, van Tinteren H, Coulomb A, Gessler M, Williams RD, Pritchard-Jones K.

J Clin Oncol. 2016 Sep 10;34(26):3195-203. doi: 10.1200/JCO.2015.66.0001. Epub 2016 Jul 18.

4.

Loss of heterozygosity at 11p13 and 11p15 in Wilms tumor: a study of 22 cases from India.

Sigamani E, Wari MN, Iyer VK, Agarwala S, Sharma A, Bakhshi S, Dinda A.

Pediatr Surg Int. 2013 Mar;29(3):223-7. doi: 10.1007/s00383-012-3254-8. Epub 2013 Jan 5.

PMID:
23292539
5.

Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.

Spreafico F, Ciceri S, Gamba B, Torri F, Terenziani M, Collini P, Macciardi F, Radice P, Perotti D.

Oncotarget. 2016 Feb 23;7(8):8908-15. doi: 10.18632/oncotarget.6950.

6.

Clonality and loss of heterozygosity of WT genes are early events in the pathogenesis of nephroblastomas.

Guertl B, Ratschek M, Harms D, Jaenig U, Leuschner I, Poremba C, Hoefler G.

Hum Pathol. 2003 Mar;34(3):278-81.

PMID:
12673563
7.

WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study.

Perlman EJ, Grundy PE, Anderson JR, Jennings LJ, Green DM, Dome JS, Shamberger RC, Ruteshouser EC, Huff V.

J Clin Oncol. 2011 Feb 20;29(6):698-703. doi: 10.1200/JCO.2010.31.5192. Epub 2010 Dec 28.

8.
9.

Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.

Gratias EJ, Jennings LJ, Anderson JR, Dome JS, Grundy P, Perlman EJ.

Cancer. 2013 Nov 1;119(21):3887-94. doi: 10.1002/cncr.28239. Epub 2013 Aug 26.

10.

High frequency of loss of heterozygosity for 1p35-p36 (D1S247) in Wilms tumor.

Steinberg R, Freud E, Zer M, Ziperman I, Goshen Y, Ash S, Stein J, Zaizov R, Avigad S.

Cancer Genet Cytogenet. 2000 Mar;117(2):136-9.

PMID:
10704684
11.

Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.

Grundy P, Telzerow P, Moksness J, Breslow NE.

Med Pediatr Oncol. 1996 Nov;27(5):429-33.

PMID:
8926924
12.

Retrospective analysis of FFPE based Wilms' Tumor samples through copy number and somatic mutation related Molecular Inversion Probe Based Array.

Singh N, Sahu DK, Goel M, Kant R, Gupta DK.

Gene. 2015 Jul 10;565(2):295-308. doi: 10.1016/j.gene.2015.04.051. Epub 2015 Apr 22.

PMID:
25913740
13.

Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.

Gratias EJ, Dome JS, Jennings LJ, Chi YY, Tian J, Anderson J, Grundy P, Mullen EA, Geller JI, Fernandez CV, Perlman EJ.

J Clin Oncol. 2016 Sep 10;34(26):3189-94. doi: 10.1200/JCO.2015.66.1140. Epub 2016 Jul 11.

14.

Stratification of Wilms tumor by genetic and epigenetic analysis.

Scott RH, Murray A, Baskcomb L, Turnbull C, Loveday C, Al-Saadi R, Williams R, Breatnach F, Gerrard M, Hale J, Kohler J, Lapunzina P, Levitt GA, Picton S, Pizer B, Ronghe MD, Traunecker H, Williams D, Kelsey A, Vujanic GM, Sebire NJ, Grundy P, Stiller CA, Pritchard-Jones K, Douglas J, Rahman N.

Oncotarget. 2012 Mar;3(3):327-35.

15.

16q heterozygosity loss in Wilms' tumour in children and its clinical importance.

Skotnicka-Klonowicz G, Rieske P, Bartkowiak J, Szymik-Kantorowicz S, Daszkiewicz P, Debiec-Rychter M.

Eur J Surg Oncol. 2000 Feb;26(1):61-6.

PMID:
10718182
16.

Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.

Williams RD, Al-Saadi R, Chagtai T, Popov S, Messahel B, Sebire N, Gessler M, Wegert J, Graf N, Leuschner I, Hubank M, Jones C, Vujanic G, Pritchard-Jones K; Children's Cancer and Leukaemia Group; SIOP Wilms' Tumour Biology Group.

Clin Cancer Res. 2010 Apr 1;16(7):2036-45. doi: 10.1158/1078-0432.CCR-09-2890. Epub 2010 Mar 23.

17.

Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.

Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PR, Macklis R, Tomlinson G, Huff V, Green DM; National Wilms Tumor Study Group.

J Clin Oncol. 2005 Oct 10;23(29):7312-21. Epub 2005 Aug 29.

PMID:
16129848
18.

Profiling Loss of Heterozygosity Patterns in a Cohort of Favorable Histology Nephroblastoma Egyptian Patients: What is Consistent With the Rest of the World.

Fawzy M, Bahanassy A, Samir A, Hafez H.

Pediatr Hematol Oncol. 2015;32(8):548-56. doi: 10.3109/08880018.2015.1071902. Epub 2015 Sep 22.

PMID:
26390800
19.

Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.

Natrajan R, Little SE, Reis-Filho JS, Hing L, Messahel B, Grundy PE, Dome JS, Schneider T, Vujanic GM, Pritchard-Jones K, Jones C.

Clin Cancer Res. 2006 Dec 15;12(24):7284-93.

20.

Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group.

Bown N, Cotterill SJ, Roberts P, Griffiths M, Larkins S, Hibbert S, Middleton H, Kelsey A, Tritton D, Mitchell C.

Med Pediatr Oncol. 2002 Jan;38(1):11-21.

PMID:
11835232

Supplemental Content

Support Center